Clinical features and outcome of tuberculosis in solid organ transplant recipients

American Journal of the Medical Sciences

Volumn 334, Issue 2, 2007, Pages 106-110

  Hsu, Meng Shiuan ^a,b   Wang, Jiun Ling ^b   Ko, Wen Je ^b   Lee, Po Huang ^b   Chou, Nai Kwan ^b   Wang, Shoei Shen ^b   Chu, Shu Hsun ^a,b   Chang, Shan Chwen ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Post transplantation tuberculosis; Solid organ transplantation; Tuberculosis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; ETHAMBUTOL; ISONIAZID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; RIFAMPICIN; STREPTOMYCIN; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TUBERCULOSIS; MALE; MILIARY TUBERCULOSIS; MORTALITY; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; TACROLIMUS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 34547875728     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31812f5a4e     Document Type: Article

References (15)

1. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27:1266-77.
2. Aguado JM, Herrero JA, Gavaldá J. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplantation 1997;63:1278-86.
3. Meyers BR, Papanicolaou GA, Sheiner P, et al. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation 2000;69:64-9.
4. Sayiner A, Ece T, Duman S, et al. Tuberculosis in renal transplant recipients. Transplantation 1999;68:1268-71.
5. Yee GC, McGuire TR,. Pharmacokinetic drug interactions with cyclosporine (part 1). Clin Pharmacokinet 1990;19:319-32.
6. Körner MM, Hirata N, Tenderich G, et al. Tuberculosis in heart transplant recipients. Chest 1997;111:365-9.
7. Wu YJ. Current status of tuberculosis in Taiwan and the policy of government. Taiwan Med J 2005;48:38-40.
8. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
9. Delaney V, Sumrani N, Hong JH, et al. Mycobacterial infections in renal allograft recipients. Transplant Proc 1993;25:2288-9.
10. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005;40:581-7.
11. European best practice guidelines for renal transplantation, section IV: long-term management of the transplant recipient. IV. 7.2. Late Infections. Tuberculosis. Nephrol Dial Transplant. 2002;17(Suppl 4):39-43.
12. Modry DL, Stinson EB, Oyer PE, et al. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985;39:313-4.
13. Herreros J, Azanza J, Catalán. Infection after heart transplantation. Transplant 1991;2: 40-7.
14. Al-Sulaiman MH, Dhar JM, Al-Khader AA. Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients in immunosuppressed with cyclosporine. Transplantation 1990;50:597-8.
15. Cavusoglu C, Cicek-Saydam C, Karasu Z, et al. Mycobacterium tuberculosis infection and laboratory diagnosis in solid-organ transplant recipients. Clin Transplant 2002;16:257-61.